

David A Morrow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6983843/publications.pdf>

Version: 2024-02-01

305
papers

46,774
citations

2795

94
h-index

1851

209
g-index

315
all docs

315
docs citations

315
times ranked

32974
citing authors

#	ARTICLE	IF	CITATIONS
1	Third Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2012, 126, 2020-2035.	1.6	2,722
2	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	1.0	2,687
3	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	1.2	2,558
4	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 2551-2567.	1.0	2,447
5	Fourth Universal Definition of Myocardial Infarction (2018). <i>Journal of the American College of Cardiology</i> , 2018, 72, 2231-2264.	1.2	2,285
6	C-Reactive Protein Levels and Outcomes after Statin Therapy. <i>New England Journal of Medicine</i> , 2005, 352, 20-28.	13.9	2,103
7	Fourth Universal Definition of Myocardial Infarction (2018). <i>Circulation</i> , 2018, 138, e618-e651.	1.6	1,858
8	TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. <i>Circulation</i> , 2000, 102, 2031-2037.	1.6	1,302
9	The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2001, 345, 1014-1021.	13.9	1,217
10	Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General Population. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2503.	3.8	936
11	Angiotensinâ€“Nepriylsin Inhibition in Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2019, 380, 539-548.	13.9	848
12	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. <i>New England Journal of Medicine</i> , 2012, 366, 1404-1413.	13.9	841
13	Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017, 376, 2053-2064.	13.9	761
14	C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1460-1465.	1.2	718
15	Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2002, 105, 1760-1763.	1.6	680
16	Ability of Minor Elevations of Troponins I and T to Predict Benefit From an Early Invasive Strategy in Patients With Unstable Angina and Non-ST Elevation Myocardial Infarction<SUBTITLE>Results From a Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 2405.	3.8	585
17	Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2006, 354, 1477-1488.	13.9	556
18	Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Nonâ€“ST-Elevation Acute Coronary Syndromes<SUBTITLE>The MERLIN-TIMI 36 Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1775.	3.8	448

#	ARTICLE	IF	CITATIONS
19	Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndrome. <i>Circulation</i> , 2007, 116, 1647-1652.	1.6	422
20	Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Nonâ€“ST-elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1264-1272.	1.2	393
21	Prevalence and Determinants of Troponin T Elevation in the General Population. <i>Circulation</i> , 2006, 113, 1958-1965.	1.6	383
22	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2007, 53, 552-574.	1.5	383
23	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018, 137, 961-972.	1.6	368
24	Soluble CD40L. <i>Circulation</i> , 2003, 108, 1049-1052.	1.6	367
25	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. <i>Circulation</i> , 2007, 115, e356-75.	1.6	348
26	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. <i>Journal of the American College of Cardiology</i> , 2021, 78, e187-e285.	1.2	336
27	Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1988-1995.	1.2	320
28	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2021, 144, e368-e454.	1.6	319
29	Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease. <i>Circulation</i> , 2007, 115, 1528-1536.	1.6	316
30	Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2008, 117, 1936-1944.	1.6	290
31	Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial. <i>Circulation</i> , 2006, 114, 281-288.	1.6	284
32	Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation. <i>Circulation</i> , 2020, 142, 2095-2106.	1.6	269
33	Vorapaxar in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2013, 127, 1522-1529.	1.6	261
34	COVID-19 for the Cardiologist. <i>JACC Basic To Translational Science</i> , 2020, 5, 518-536.	1.9	256
35	A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. <i>Lancet, The</i> , 2001, 358, 1571-1575.	6.3	245
36	Evolution of Critical Care Cardiology: Transformation of the Cardiovascular Intensive Care Unit and the Emerging Need for New Medical Staffing and Training Models. <i>Circulation</i> , 2012, 126, 1408-1428.	1.6	240

#	ARTICLE	IF	CITATIONS
37	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure. <i>Clinical Chemistry</i> , 2007, 53, 2086-2096.	1.5	239
38	Fourth Universal Definition of Myocardial Infarction (2018). , 2018, 13, 305-338.		237
39	Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. <i>European Heart Journal</i> , 2008, 30, 162-169.	1.0	233
40	Epidemiology of Shock in Contemporary Cardiac Intensive Care Units. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005618.	0.9	232
41	Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. <i>Journal of the American College of Cardiology</i> , 2000, 36, 1812-1817.	1.2	219
42	Future of Biomarkers in Acute Coronary Syndromes. <i>Circulation</i> , 2003, 108, 250-252.	1.6	219
43	Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1644-1648.	1.2	219
44	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1021-1034.	1.2	211
45	Lipoprotein-Associated Phospholipase A 2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin) Tj ETQq1 1 0.784314 rgBT /Overlock 1745-1752.	1.6	209
46	Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury. <i>Circulation</i> , 2019, 140, 1661-1678.	1.6	207
47	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 ^Å P-TIMI 50 trial. <i>Lancet, The</i> , 2012, 380, 1317-1324.	6.3	202
48	B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, 335-339.	1.2	196
49	Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients With Unstable Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2866.	3.8	194
50	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1591.	3.8	190
51	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2007, 53, 547-551.	1.5	188
52	Unstable Angina. <i>Circulation</i> , 2013, 127, 2452-2457.	1.6	186
53	Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. <i>European Heart Journal</i> , 2007, 28, 2077-2086.	1.0	172
54	Efficacy of Ranolazine in Patients With Chronic Angina. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1510-1516.	1.2	171

#	ARTICLE	IF	CITATIONS
55	Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2006, 114, 550-557.	1.6	168
56	Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. <i>European Heart Journal</i> , 2008, 29, 1096-1102.	1.0	168
57	The Verdict Is Still Out. <i>Circulation</i> , 2006, 113, 2128-2151.	1.6	167
58	Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2Â°P)-TIMI 50 trial. <i>American Heart Journal</i> , 2009, 158, 335-341.e3.	1.2	166
59	Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2016, 133, 997-1005.	1.6	163
60	Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials. <i>Journal of the American College of Cardiology</i> , 2003, 42, 7-16.	1.2	160
61	Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT-TIMI 22 Study. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2326-2331.	1.2	157
62	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 911-921.	1.2	157
63	Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Trombolysis in Myocardial Infarction 38. <i>Circulation</i> , 2009, 119, 2758-2764.	1.6	155
64	American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death. <i>Circulation</i> , 2012, 125, 577-583.	1.6	153
65	Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 520-527.	1.2	152
66	Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2002, 89, 463-465.	0.7	151
67	Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. <i>American Heart Journal</i> , 2008, 155, 49-55.	1.2	151
68	Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial. <i>Circulation</i> , 2009, 119, 2032-2039.	1.6	144
69	Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2117-2124.	1.2	143
70	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , 2016, 134, 304-313.	1.6	143
71	Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial. <i>Clinical Chemistry</i> , 2012, 58, 257-266.	1.5	140
72	Demographics, Care Patterns, and Outcomes of Patients Admitted to Cardiac Intensive Care Units. <i>JAMA Cardiology</i> , 2019, 4, 928.	3.0	139

#	ARTICLE	IF	CITATIONS
73	Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2002, 40, 71-77.	1.2	138
74	Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 203-210.	1.1	138
75	Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 424-430.	1.1	136
76	Novel biomarkers in cardiovascular disease: Update 2010. <i>American Heart Journal</i> , 2010, 160, 583-594.	1.2	136
77	Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. <i>Circulation</i> , 2019, 139, 2285-2288.	1.6	129
78	Long-Term Prognostic Value of Neopterin. <i>Circulation</i> , 2007, 115, 3071-3078.	1.6	125
79	Elevations in Troponin T and I Are Associated With Abnormal Tissue Level Perfusion. <i>Circulation</i> , 2002, 106, 202-207.	1.6	122
80	A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2364-2373.	1.2	122
81	Positive Pressure Ventilation in the Cardiac Intensive Care Unit. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1532-1553.	1.2	122
82	Cardiogenic Shock After Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1840.	3.8	121
83	Being Rational about (Im)precision: A Statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the Definition of Myocardial Infarction. <i>Clinical Chemistry</i> , 2010, 56, 941-943.	1.5	120
84	Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin I. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2118-2124.	1.2	120
85	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
86	Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2548.	3.8	117
87	Clinical Efficacy of Three Assays for Cardiac Troponin I for Risk Stratification in Acute Coronary Syndromes: A Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. <i>Clinical Chemistry</i> , 2000, 46, 453-460.	1.5	113
88	Relationship Between Uncontrolled Risk Factors and C-Reactive Protein Levels in Patients Receiving Standard or Intensive Statin Therapy for Acute Coronary Syndromes in the PROVE IT-TIMI 22 Trial. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1417-1424.	1.2	113
89	Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized With COVID-19: Findings From the American Heart Association's COVID-19 Cardiovascular Disease Registry. <i>Circulation</i> , 2021, 143, 2332-2342.	1.6	113
90	Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e218828.	2.8	110

#	ARTICLE	IF	CITATIONS
91	Relationship Between Nonsustained Ventricular Tachycardia After Non-“ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death. <i>Circulation</i> , 2010, 122, 455-462.	1.6	109
92	Association of Elevated B-Type Natriuretic Peptide Levels With Angiographic Findings Among Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, 564-568.	1.2	107
93	Economic Impact of Angina After an Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 344-353.	0.9	107
94	Brain Natriuretic Peptide Measurement in Acute Coronary Syndromes. <i>Circulation</i> , 2002, 106, 2868-2870.	1.6	103
95	Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1059-1077.	1.2	103
96	Inflammatory Biomarkers in Acute Coronary Syndromes. <i>Circulation</i> , 2006, 113, e72-5.	1.6	100
97	Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	100
98	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Circulation</i> , 2019, 139, 760-771.	1.6	99
99	2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2021, 144, e368-e454.	1.6	99
100	Cardiovascular Risk Prediction in Patients With Stable and Unstable Coronary Heart Disease. <i>Circulation</i> , 2010, 121, 2681-2691.	1.6	98
101	A current review of COVID-19 for the cardiovascular specialist. <i>American Heart Journal</i> , 2020, 226, 29-44.	1.2	97
102	Use of Temporary Mechanical Circulatory Support for Management of Cardiogenic Shock Before and After the United Network for Organ Sharing Donor Heart Allocation System Changes. <i>JAMA Cardiology</i> , 2020, 5, 703.	3.0	93
103	Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1309-1317.	1.2	91
104	Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke. <i>Stroke</i> , 2013, 44, 691-698.	1.0	89
105	Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: Observations from the PROTECT-TIMI 30 Trial. <i>American Heart Journal</i> , 2009, 158, 386-391.	1.2	86
106	Prognostic Performance of Multiple Biomarkers in Patients With Non-“ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1644-1653.	1.2	86
107	Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2005, 149, 217-226.	1.2	83
108	Relation of Coronary Atherosclerosis Determined by Electron Beam Computed Tomography and Plasma Levels of N-terminal Pro-Brain Natriuretic Peptide in a Multiethnic Population-Based Sample (The Dallas Heart Study). <i>American Journal of Cardiology</i> , 2005, 96, 1284-1289.	0.7	78

#	ARTICLE	IF	CITATIONS
109	Evaluation of High-Sensitivity Assays for Cardiac Troponin. <i>Clinical Chemistry</i> , 2009, 55, 5-8.	1.5	78
110	Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial. <i>European Heart Journal</i> , 2011, 32, 697-705.	1.0	77
111	Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk. <i>JAMA Cardiology</i> , 2016, 1, 989.	3.0	77
112	Prognostic Performance of a High-Sensitivity Cardiac Troponin I Assay in Patients with Non-ST-Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2014, 60, 158-164.	1.5	74
113	B-Type Natriuretic Peptide and the Effect of Ranolazine in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1189-1196.	1.2	73
114	Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2015, 131, 1047-1053.	1.6	73
115	Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. <i>American Journal of Cardiology</i> , 2002, 90, 303-305.	0.7	72
116	The Search for a Biomarker of Cardiac Ischemia. <i>Clinical Chemistry</i> , 2003, 49, 537-539.	1.5	71
117	A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 359-364.	1.0	71
118	Effect of Ranolazine on A1C and Glucose Levels in Hyperglycemic Patients With Non-ST Elevation Acute Coronary Syndrome. <i>Diabetes Care</i> , 2010, 33, 1163-1168.	4.3	66
119	2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2218-2261.	1.2	66
120	Implications of Upstream Glycoprotein IIb/IIIa Inhibition and Coronary Artery Stenting in the Invasive Management of Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2004, 109, 874-880.	1.6	65
121	Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2016, 1, 999.	3.0	64
122	Admission diagnosis and mortality risk prediction in a contemporary cardiac intensive care unit population. <i>American Heart Journal</i> , 2020, 224, 57-64.	1.2	64
123	Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. <i>American Heart Journal</i> , 2006, 151, 1186.e1-1186.e9.	1.2	63
124	Clinical Features and Outcomes of Women With Unstable Ischemic Heart Disease. <i>Circulation</i> , 2010, 121, 1809-1817.	1.6	62
125	Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. <i>Journal of the American Heart Association</i> , 2015, 4, e001505.	1.6	62
126	Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". <i>Circulation</i> , 2015, 132, e121-2.	1.6	61

#	ARTICLE	IF	CITATIONS
127	Rationale and design of the comParlson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. American Heart Journal, 2018, 198, 145-151.	1.2	60
128	Correlation between the TIMI risk score and high-risk angiographic findings in non-â€“ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. American Heart Journal, 2005, 149, 846-850.	1.2	59
129	Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. European Heart Journal, 2019, 40, 3345-3352.	1.0	59
130	Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. European Heart Journal, 2005, 26, 682-688.	1.0	58
131	Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry. Circulation: Heart Failure, 2019, 12, e006635.	1.6	58
132	Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure. JAMA Cardiology, 2020, 5, 202.	3.0	57
133	2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Journal of Cardiovascular Computed Tomography, 2022, 16, 54-122.	0.7	57
134	Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. Heart, 2011, 97, 1782-1787.	1.2	56
135	Prospective Evaluation of Pregnancy-Associated Plasma Protein-A and Outcomes in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2012, 60, 332-338.	1.2	55
136	Contemporary Management of Severe-â€“Acute Kidney Injury and Refractory Cardiorenal Syndrome. Journal of the American College of Cardiology, 2020, 76, 1084-1101.	1.2	55
137	Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death. Clinical Chemistry, 2009, 55, 265-273.	1.5	54
138	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin) Tj ETQq0 0 0 rgBT /Overl64 10 Tf 5	1.2	54
139	Outcomes of Women Compared With Men After Non-â€“ST-Segment Elevation Acute-â€“Coronary Syndromes. Journal of the American College of Cardiology, 2019, 74, 3013-3022.	1.2	54
140	Application of the Thrombolysis In Myocardial Infarction Risk Index in Non-â€“ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2006, 47, 1553-1558.	1.2	53
141	Organization and staffing practices in US cardiac intensive care units: a survey on behalf of the American Heart Association Writing Group on the Evolution of Critical Care Cardiology. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 3-8.	0.4	53
142	Evaluation of the AccuTnI Cardiac Troponin I Assay for Risk Assessment in Acute Coronary Syndromes. Clinical Chemistry, 2003, 49, 1396-1398.	1.5	51
143	COVID-19 and Disruptive Modifications to Cardiac Critical Care Delivery. Journal of the American College of Cardiology, 2020, 76, 72-84.	1.2	51
144	Ischemia Detected on Continuous Electrocardiography After Acute Coronary Syndrome. Journal of the American College of Cardiology, 2009, 53, 1411-1421.	1.2	50

#	ARTICLE	IF	CITATIONS
145	American Heart Association COVID-19 CVD Registry Powered by Get With The Guidelines. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006967.	0.9	48
146	Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trialâ€“Thrombolysis in Myocardial Infarction 22 (PROVE ITâ€“TIMI 22). <i>American Heart Journal</i> , 2011, 161, 1147-1155.e1.	1.2	46
147	Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. <i>Europace</i> , 2015, 17, 32-37.	0.7	46
148	Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2020, 5, 1236.	3.0	46
149	Derivation and Validation of a Novel Cardiac Intensive Care Unit Admission Risk Score for Mortality. <i>Journal of the American Heart Association</i> , 2019, 8, e013675.	1.6	45
150	Troponins in acute coronary syndromes. <i>Progress in Cardiovascular Diseases</i> , 2004, 47, 177-188.	1.6	44
151	Effects of Ranolazine on Disease-Specific Health Status and Quality of Life Among Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 107-115.	0.9	44
152	Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. <i>EClinicalMedicine</i> , 2020, 26, 100504.	3.2	44
153	Coronary Stent Thrombosis With Vorapaxar Versus Placebo. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2309-2317.	1.2	41
154	The Range of Cardiogenic Shock Survival by Clinical Stage: Data From the Critical Care Cardiology Trials Network Registry. <i>Critical Care Medicine</i> , 2021, 49, 1293-1302.	0.4	41
155	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. <i>Circulation</i> , 2016, 134, 861-871.	1.6	40
156	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2015, 132, 1871-1879.	1.6	39
157	Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2157-2164.	1.1	39
158	Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. <i>Clinica Chimica Acta</i> , 2004, 346, 119-128.	0.5	37
159	De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry. <i>Journal of Cardiac Failure</i> , 2021, 27, 1073-1081.	0.7	37
160	Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With ST-Segment Elevation Myocardial Infarction Also Treated With Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2256-2263.	1.2	36
161	Organizational Structure, Staffing, Resources, and Educational Initiatives in Cardiac Intensive Care Units in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, e003864.	0.9	36
162	Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. <i>European Heart Journal</i> , 2010, 31, 2103-2110.	1.0	35

#	ARTICLE	IF	CITATIONS
163	Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	35
164	Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. <i>Heart</i> , 2012, 98, 786-791.	1.2	34
165	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 473.	3.0	33
166	Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 18-25.	0.4	32
167	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2018, 138, 1963-1973.	1.6	32
168	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1057-1068.	1.2	32
169	Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1034-1048.	1.2	32
170	Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e015331.	1.6	32
171	Rationale and design of the Losmapimod To Inhibit p38 MAP kinase as a Therapeutic target and modify outcomes after an acute coronary syndrome trial. <i>American Heart Journal</i> , 2015, 169, 622-630.e6.	1.2	31
172	New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2318-2326.	1.2	30
173	Clinician's Guide to Early Rule-Out Strategies With High-Sensitivity Cardiac Troponin. <i>Circulation</i> , 2017, 135, 1612-1616.	1.6	30
174	High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Tirofiban in Patients With Type 2 Diabetes) Trial. <i>Metabolism</i> , 2018, 20, 654-659.	2.2	30
175	Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. <i>Diabetes Care</i> , 2018, 41, 1510-1515.	4.3	30
176	Epidemiology and causes of cardiogenic shock. <i>Current Opinion in Critical Care</i> , 2021, 27, 401-408.	1.6	30
177	Modes and timing of death in 66%252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018, 39, 3810-3820.	1.0	28
178	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. <i>European Journal of Heart Failure</i> , 2022, 24, 1066-1076.	2.9	28
179	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. <i>American Heart Journal</i> , 2020, 219, 1-8.	1.2	27
180	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020, 5, 1255.	3.0	27

#	ARTICLE	IF	CITATIONS
181	Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e007034.	1.6	27
182	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2021, 42, 1698-1706.	1.0	27
183	Real-World Application of ΔTroponin. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1239-1241.	1.2	26
184	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the <sc>EXAMINE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 962-969.	2.2	26
185	Validation of the Seattle angina questionnaire in women with ischemic heart disease. <i>American Heart Journal</i> , 2018, 201, 117-123.	1.2	25
186	Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. <i>Diabetes Care</i> , 2018, 41, 577-585.	4.3	25
187	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1095-1106.	1.2	25
188	Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the <sc>MERLINâ€TIMI</sc> 36 Trial. <i>Clinical Cardiology</i> , 2015, 38, 469-475.	0.7	24
189	Editorâ€™s Choice-Prospective registry of cardiac critical illness in a modern tertiary care Cardiac Intensive Care Unit. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 755-761.	0.4	24
190	Positive Pressure Ventilation in Cardiogenic Shock: Review of the Evidence and Practical Advice for Patients With Mechanical Circulatory Support. <i>Canadian Journal of Cardiology</i> , 2020, 36, 300-312.	0.8	24
191	Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2Â°P-TIMI 50 trial. <i>Vascular Medicine</i> , 2020, 25, 124-132.	0.8	24
192	Defining a Role for Novel Biomarkers in Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2008, 54, 1424-1431.	1.5	23
193	Advanced Respiratory Support in the Contemporary Cardiac ICU. , 2020, 2, e0182.		23
194	Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction. <i>JAMA Cardiology</i> , 2020, 5, 787.	3.0	23
195	Troponins in Patients with Acute Coronary Syndromes: Biologic, Diagnostic, and Therapeutic Implications. <i>Cardiovascular Toxicology</i> , 2001, 1, 105-110.	1.1	22
196	Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI) Tj ETQq0 0 0 rgBT./Overlock 10 Tf 50	0.7	22
197	Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-STâ€™elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. <i>American Heart Journal</i> , 2004, 148, 173-180.	1.2	22
198	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018, 137, 684-692.	1.6	22

#	ARTICLE	IF	CITATIONS
199	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. <i>Circulation</i> , 2021, 143, 685-695.	1.6	22
200	Trends in Cardiac Critical Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, e004010.	0.9	21
201	The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. <i>European Heart Journal</i> , 2004, 25, 1139-1145.	1.0	20
202	Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatmentâ€“Thrombolysis In Myocardial Infarction study 25 (ExTRACTâ€“TIMI 25) trial. <i>American Heart Journal</i> , 2007, 154, 1078-1084.e1.	1.2	19
203	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2Â°P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017, 63, 307-315.	1.5	19
204	Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. <i>JACC: Heart Failure</i> , 2020, 8, 834-843.	1.9	19
205	Thrombus Precursor Protein and Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2422-2429.	1.2	18
206	Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction: A Report from the ACTION Registryâ€“GWTGâ„¸. <i>Clinical Chemistry</i> , 2013, 59, 1205-1214.	1.5	18
207	Relation of T-Wave Alternans to Mortality and Nonsustained Ventricular Tachycardia in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome from the MERLIN-TIMI 36 Trial of Ranolazine Versus Placebo. <i>American Journal of Cardiology</i> , 2014, 114, 17-23.	0.7	18
208	The Unmet Need for Addressing Cardiac Issues in Intensive Care Research*. <i>Critical Care Medicine</i> , 2015, 43, 128-134.	0.4	18
209	Plasma Omegaâ€“3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLINâ€“TIMI 36. <i>Journal of the American Heart Association</i> , 2021, 10, e017401.	1.6	18
210	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 895-902.	0.8	18
211	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.	1.6	18
212	Evaluation of a clinical pathway for sedation and analgesia of mechanically ventilated patients in a cardiac intensive care unit (CICU): The Brigham and Womenâ€™s Hospital Levine CICU sedation pathways. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 299-305.	0.4	17
213	Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 431-440.	0.4	17
214	SCH 530348: a novel oral thrombin receptor antagonist. <i>Future Cardiology</i> , 2009, 5, 435-442.	0.5	16
215	Myocardial Ischemia and Ventricular Tachycardia on Continuous Electrocardiographic Monitoring and Risk of Cardiovascular Outcomes After Nonâ€“ST-Segment Elevation Acute Coronary Syndrome (from the MERLIN-TIMI 36 Trial). <i>American Journal of Cardiology</i> , 2011, 108, 1373-1381.	0.7	16
216	ECG Morphological Variability in Beat Space for Risk Stratification After Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2014, 3, e000981.	1.6	16

#	ARTICLE	IF	CITATIONS
217	Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non-ST-Elevation Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2014, 37, 350-356.	0.7	16
218	Incidence, underlying conditions, and outcomes of patients receiving acute renal replacement therapies in tertiary cardiac intensive care units: An analysis from the Critical Care Cardiology Trials Network Registry. <i>American Heart Journal</i> , 2020, 222, 8-14.	1.2	16
219	Biomarkers for Risk Assessment in Atrial Fibrillation. <i>Clinical Chemistry</i> , 2021, 67, 87-95.	1.5	16
220	The future of biomarkers in the management of patients with acute coronary syndromes. <i>Current Opinion in Cardiology</i> , 2008, 23, 309-314.	0.8	15
221	The Fourth Universal Definition of Myocardial Infarction and the Emerging Importance of Myocardial Injury. <i>Circulation</i> , 2020, 141, 172-175.	1.6	15
222	N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID-19 in a Nationwide Hospitalized Cohort. <i>Journal of the American Heart Association</i> , 2021, 10, e022913.	1.6	15
223	Ranolazine in patients with angina and coronary artery disease. <i>Current Cardiology Reports</i> , 2007, 9, 272-278.	1.3	14
224	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 322-323.	1.2	14
225	Outcomes in patients undergoing percutaneous ventricular assist device implantation for cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 108-116.	0.4	14
226	Cardiac safety research consortium shock think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. <i>American Heart Journal</i> , 2020, 230, 93-97.	1.2	14
227	Hepatotoxicity associated with methotrexate therapy in a dog. <i>Journal of Small Animal Practice</i> , 1982, 23, 659-666.	0.5	13
228	Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 310-316.	1.0	13
229	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 ^Å P)-TIMI 50. <i>Journal of the American Heart Association</i> , 2016, 5,	1.6	13
230	Cardiovascular Disease: Impact of Biomarkers, Proteomics, and Genomics. <i>Clinical Chemistry</i> , 2017, 63, 1-4.	1.5	13
231	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021, 44, 2573-2581.	4.3	13
232	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 382-391.	0.7	12
233	Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008477.	1.6	12
234	Hemodynamic Significance of Periprocedural Myocardial Injury Assessed With N-Terminal Pro-B-Type Natriuretic Peptide After Percutaneous Coronary Intervention in Patients With Stable and Unstable Coronary Artery Disease (from the JUMBO-TIMI 26 Trial). <i>American Journal of Cardiology</i> , 2007, 99, 344-348.	0.7	11

#	ARTICLE	IF	CITATIONS
235	Novel Biomarkers in Cardiovascular Disease. <i>Cardiology in Review</i> , 2012, 20, 111-117.	0.6	11
236	Biomarker of Collagen Turnover (Câ€T-terminal Telopeptide) andâ€Prognosis in Patients With Nonâ€STâ€Elevation Acute Coronaryâ€Syndromes. <i>Journal of the American Heart Association</i> , 2019, 8, e011444.	1.6	11
237	Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTEMI-ACS. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1084-1092.	1.4	11
238	Angiotensin-Neprilysin Inhibition in Black Americans. <i>JACC: Heart Failure</i> , 2020, 8, 859-866.	1.9	11
239	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	1.2	11
240	Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	11
241	End-of-life care in the cardiac intensive care unit: a contemporary view from the Critical Care Cardiology Trials Network (CCCTN) Registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 190-197.	0.4	11
242	Evidence-Based Algorithms Using High-Sensitivity Cardiac Troponin in the Emergency Department. <i>JAMA Cardiology</i> , 2016, 1, 379.	3.0	10
243	Progressive myocardial injury is associated with mortality in the acute respiratory distress syndrome. <i>Journal of Critical Care</i> , 2018, 48, 26-31.	1.0	10
244	Spectral Energy of ECG Morphologic Differences to Predict Death. <i>Cardiovascular Engineering (Dordrecht, Netherlands)</i> , 2009, 9, 18-26.	1.0	9
245	One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 Trial. <i>European Heart Journal</i> , 2010, 31, 2097-2102.	1.0	9
246	Hospital triage of acute myocardial infarction: Is admission to the coronary care unit still necessary?. <i>American Heart Journal</i> , 2016, 175, 172-174.	1.2	9
247	Utilization and outcomes of early respiratory support in 6.5 million acute heart failure hospitalizations. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 72-80.	1.8	9
248	Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 675-681.	1.0	9
249	Trends in Therapy and Outcomes Associated With Respiratory Failure in Patients Admitted to the Cardiac Intensive Care Unit. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 543-554.	1.3	9
250	Troponins in Acute Coronary Syndromes. <i>Seminars in Vascular Medicine</i> , 2003, 03, 363-374.	2.1	8
251	Evidence-Based Redesign of the Cardiacâ€Intensive Care Unit â€—. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2649-2651.	1.2	8
252	Use of high sensitivity cardiac troponin assays as an adjunct to cardiac stress testing. <i>Clinical Biochemistry</i> , 2016, 49, 419-420.	0.8	8

#	ARTICLE	IF	CITATIONS
253	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2Â°P-TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 164-172.	0.4	8
254	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUSâ€™TIMI 54. <i>Journal of the American Heart Association</i> , 2018, 7, e009260.	1.6	8
255	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. <i>American Heart Journal</i> , 2022, 246, 136-143.	1.2	8
256	Epidemiology of Acute Heart Failure in Critically Ill Patients With COVID-19: An Analysis From the Critical Care Cardiology Trials Network. <i>Journal of Cardiac Failure</i> , 2022, 28, 675-681.	0.7	8
257	Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 353-360.	1.0	7
258	Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assayâ€™s Limit of Detection?. <i>Clinical Chemistry</i> , 2020, 66, 1146-1149.	1.5	7
259	Left ventricle unloading strategies in ECMO: A singleâ€™center experience. <i>Journal of Cardiac Surgery</i> , 2020, 35, 1514-1524.	0.3	7
260	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2Â°Pâ€™TIMI 50. <i>Journal of the American Heart Association</i> , 2021, 10, e018673.	1.6	7
261	Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. <i>Circulation</i> , 2021, 144, 249-251.	1.6	7
262	Contemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel Approach. <i>Circulation: Heart Failure</i> , 2021, 14, .	1.6	7
263	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. <i>Point of Care</i> , 2007, 6, 215-222.	0.5	6
264	Incidence, predictors and prognosis of respiratory support in non-ST segment elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 200-206.	0.4	6
265	Potential growth in cardiogenic shock research though an international registry collaboration: the merits and challenges of a <i>Hub-of-Spokes</i> model. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 3-5.	0.4	6
266	Cardiac troponin elevation after elective PCI: adding infarct to major injury. <i>European Heart Journal</i> , 2021, 42, 335-338.	1.0	6
267	OUP accepted manuscript. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 963-965.	0.4	6
268	Epidemiology and Management of STâ€™Segmentâ€™Elevation Myocardial Infarction in Patients With COVIDâ€™19: A Report From the American Heart Association COVIDâ€™19 Cardiovascular Disease Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024451.	1.6	6
269	Care Setting Intensity and Outcomes After Emergency Department Presentation Among Patients With Acute Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	5
270	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2Â°P-TIMI 50). <i>American Journal of Cardiology</i> , 2016, 117, 1055-1058.	0.7	5

#	ARTICLE	IF	CITATIONS
271	The Changing Face of Cardiogenic Shock. Journal of the American College of Cardiology, 2019, 73, 1792-1794.	1.2	5
272	Implementation of an Emergency Department High-Sensitivity Troponin Chest Pain Pathway in the United States. Critical Pathways in Cardiology, 2019, 18, 1-4.	0.2	5
273	Respiratory support in acute heart failure with preserved vs reduced ejection fraction. Clinical Cardiology, 2020, 43, 320-328.	0.7	5
274	Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2 ^Â P-TIMI 50 Trial. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 190-199.	0.4	5
275	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction â€“ findings from the LATITUDEâ€“TIMI 60 trial. American Heart Journal, 2022, 243, 147-157.	1.2	5
276	Patients With Acute Coronary Syndromes Admitted to Contemporary Cardiac Intensive Care Units: Insights From the CCCTN Registry. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	0.9	5
277	Soluble interleukin-13Î±1: a circulating regulator of glucose. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E663-E671.	1.8	4
278	ST-Segment Elevation Myocardial Infarction. , 2012, , 1111-1177.		4
279	Where Are we with Vitamin E?. , 1998, 5, 209-214.		3
280	RESPONSE: Training in Critical Care Cardiology. Journal of the American College of Cardiology, 2018, 72, 1174-1175.	1.2	3
281	Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2 ^Â P-TIMI 50 trial. Vascular Medicine, 2019, 24, 159-161.	0.8	3
282	Beyond the ISCHEMIA Trial: Revascularization for Stable Ischemic Heart Disease in Patients With Highâ€“Risk Coronary Anatomical Features. Journal of the American Heart Association, 2021, 10, e019974.	1.6	3
283	A pragmatic lab-based tool for risk assessment in cardiac critical care: data from the Critical Care Cardiology Trials Network (CCCTN) Registry. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 252-257.	0.4	3
284	Preprocedural C-Reactive Protein for Risk Prediction Before Percutaneous Coronary Intervention (PCI): A US Perspective. Clinical Chemistry, 2004, 50, 1489-1491.	1.5	2
285	In Search of the 1-Hour Rule-Out for Acute Myocardial Infarction. Clinical Chemistry, 2015, 61, 1427-1429.	1.5	2
286	High-Sensitivity Troponin in the Triage of Acute Decompensated Heart Failure âˆ—. JACC: Heart Failure, 2016, 4, 600-602.	1.9	2
287	Practice pattern of use of high sensitivity troponin in the outpatient settings. Clinical Cardiology, 2020, 43, 1573-1578.	0.7	2
288	New clues for optimal diagnosis and treatment of an old foe: the acute aortic syndrome. European Heart Journal: Acute Cardiovascular Care, 2020, 9, S1-S2.	0.4	2

#	ARTICLE	IF	CITATIONS
289	Closing the Gap: Insights into the Epidemiology of Heart Failure Care from the Critical Care Cardiology Trials Network. <i>Journal of Cardiac Failure</i> , 2021, 27, 1146-1147.	0.7	2
290	Appointment as patient advocacy associate editor. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 275-275.	0.4	2
291	Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease. <i>Future Cardiology</i> , 2006, 2, 85-91.	0.5	1
292	Moving toward Personalized Medicine. , 0, , 205-227.		1
293	Improving prediction of anticoagulant-related major bleeding in atrial fibrillation: The search for new biomarkers. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2674-2676.	1.9	1
294	Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021412.	1.6	1
295	A Multimarker Approach to Evaluation of Patients With Acute Coronary Syndrome. , 2006, , 545-558.		1
296	Percutaneous right ventricular assist device-supported ventricular tachycardia ablation in a patient with severe right ventricular dysfunction. <i>HeartRhythm Case Reports</i> , 2020, 6, 72-76.	0.2	1
297	Appropriate invasive and conservative treatment approaches for patients with non-ST-elevation MI. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006, 8, 13-21.	0.4	0
298	Prognostic Value of B-Type Natriuretic Peptide in Unstable Coronary Artery Disease—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1895.	3.8	0
299	Response to Letters Regarding Article, “Relationship Between Nonsustained Ventricular Tachycardia After Non-ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death: Observations From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial”; <i>Circulation</i> , 2011, 123, .	1.6	0
300	Death or revascularization among nonadmitted ED patients with low-positive vs negative troponin T results. <i>American Journal of Emergency Medicine</i> , 2014, 32, 923-928.	0.7	0
301	De-escalation of support with venoarterial extracorporeal membrane oxygenation and Impella for cardiogenic shock. <i>European Journal of Heart Failure</i> , 2018, 20, 621-622.	2.9	0
302	RESPONSE: Transition to Early Career in Critical Care Cardiology. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1730.	1.2	0
303	Which patients with acute coronary syndrome need the cardiac intensive care unit: tuning the tools for risk stratification. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 543-545.	0.4	0
304	SPOT the DIAGNOSIS. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 240-240.	0.4	0
305	How to implement novel diagnostic algorithms for non-ST-segment elevation myocardial infarction in the emergency department. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 75-76.	0.4	0